October 9, 2026

COMPASS Pathways Plc (CMPS) Investor Outlook: Navigating a Potential 107% Upside in the Mental Health Sector

For investors eyeing the healthcare sector, COMPASS Pathways Plc (NASDAQ: CMPS) presents a compelling case with a significant potential upside of 107.06%. As a biotechnology firm..

Akebia Therapeutics, Inc. (AKBA): Investor Outlook Highlights 380% Potential Upside

Akebia Therapeutics, Inc. (NASDAQ: AKBA), a biopharmaceutical company specializing in therapeutics for kidney diseases, presents a compelling, albeit risky, opportunity for investors. With a market capitalization..

LifeMD, Inc. (LFMD) Stock Analysis: Exploring a 206.6% Potential Upside Amidst Telehealth Expansion

LifeMD, Inc. (NASDAQ: LFMD), a healthcare company specializing in direct-to-patient telehealth services, presents an intriguing opportunity for investors, marked by a notable 206.6% potential upside based..

Amylyx Pharmaceuticals (AMLX) Stock Analysis: 55.75% Potential Upside Amidst Strong Buy Ratings

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), a clinical-stage pharmaceutical company based in Cambridge, Massachusetts, is making waves in the healthcare sector, specifically within the niche of specialty..

Inventiva S.A. (IVA) Stock Analysis: A Deep Dive into Its 357% Upside Potential

Inventiva S.A. – American Depositary Receipts (IVA) stands at a fascinating juncture for investors, offering a compelling narrative within the biotech sector. This France-based clinical-stage biopharmaceutical..

Fulgent Genetics, Inc. (FLGT) Stock Analysis: Navigating a Transformative Path in Diagnostics with a Challenging Financial Outlook

Fulgent Genetics, Inc. (NASDAQ: FLGT) is a noteworthy player in the healthcare sector, specifically within the diagnostics and research industry. Headquartered in El Monte, California, the..

KalVista Pharmaceuticals, Inc. (KALV) Stock Analysis: A Steady Path in the Biotech Sector

KalVista Pharmaceuticals, Inc. (KALV), a notable player in the biotechnology industry, presents an intriguing case for investors focusing on the healthcare sector. As a biopharmaceutical company..

Evolus, Inc. (EOLS) Stock Analysis: Target Price Signals a 92% Upside for Investors

For investors with a keen eye on the healthcare sector, Evolus, Inc. (NASDAQ: EOLS) presents an intriguing opportunity. Specializing in the performance beauty segment, Evolus is..

Tectonic Therapeutic, Inc. (TECX) Stock Analysis: A Potential Upside of 236.81% in the Biotech Sector

Tectonic Therapeutic, Inc. (NASDAQ: TECX) is capturing investors’ attention with its groundbreaking advancements in biotechnology and a staggering potential upside of 236.81%. A closer look at..

Xencor, Inc. (XNCR) Stock Analysis: Potential Upside of 28.23% in the Biotech Sector

Investors with an eye on the biotechnology sector may find Xencor, Inc. (NASDAQ: XNCR) an intriguing opportunity. This clinical-stage biopharmaceutical company, headquartered in Pasadena, California, is..

Precigen, Inc. (PGEN) Stock Analysis: A Biotech Gem with a 79.61% Potential Upside

Precigen, Inc. (NASDAQ: PGEN), a pioneering entity in the biotechnology sector, stands at the forefront of innovative gene and cell therapies. With a market capitalization of..

Definitive Healthcare Corp. (DH) Stock Analysis: Exploring the 96.63% Potential Upside

Definitive Healthcare Corp. (NASDAQ: DH) is a notable player in the healthcare information services sector, providing a comprehensive software-as-a-service (SaaS) healthcare commercial intelligence platform. Headquartered in..

Xeris Biopharma Holdings (XERS) Stock Analysis: A 26% Upside Potential Awaits Investors

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) is gaining attention in the healthcare sector with a promising 26.17% potential upside based on analyst projections. This commercial-stage biopharmaceutical..

uniQure N.V. (QURE) Stock Report: Exploring a 177% Potential Upside in Biotech Innovations

Investors with a keen eye on the biotechnology sector may find uniQure N.V. (NASDAQ: QURE) particularly intriguing, given its impressive potential upside of 177% as indicated..

Cullinan Therapeutics, Inc. (CGEM) Stock Analysis: A Compelling 116.39% Potential Upside Awaits Investors

Cullinan Therapeutics, Inc. (CGEM), a clinical-stage biopharmaceutical company, is capturing the attention of investors with a remarkable potential upside of 116.39%. Headquartered in Cambridge, Massachusetts, Cullinan..

Oculis Holding AG (OCS) Stock Analysis: Exploring a 322% Potential Upside in the Biotech Arena

Oculis Holding AG (OCS), a pioneering name in the realm of biotechnology, specifically targets the healthcare sector with its innovative drug candidates aimed at ophthalmic, neuro-ophthalmic,..

Delcath Systems, Inc. (DCTH) Stock Analysis: Why Investors Are Eyeing a 59.57% Potential Upside

Delcath Systems, Inc. (NASDAQ: DCTH), a standout player in the healthcare sector, specifically within the medical devices industry, is drawing significant attention from investors, thanks to..

Savara, Inc. (SVRA) Investor Outlook: Unveiling a 128.89% Potential Upside in the Biotech Sector

Savara, Inc. (NASDAQ: SVRA), a clinical-stage biopharmaceutical company specializing in rare respiratory diseases, presents a compelling investment opportunity. With a market capitalization of approximately $989.8 million,..

Pharvaris N.V. (PHVS) Stock Analysis: An 84% Potential Upside Propels Investor Interest

Pharvaris N.V. (PHVS) is capturing the attention of investors with its promising potential upside of 84.17%. As a late-stage biopharmaceutical company headquartered in Zug, Switzerland, Pharvaris..

Tilray Brands, Inc. (TLRY) Investor Outlook: Exploring a 99% Potential Upside Despite Current Challenges

Tilray Brands, Inc. (NASDAQ: TLRY), a prominent player in the healthcare sector and a leader in the drug manufacturers’ industry, has captured investor attention with its..

Search

Funds

October 9, 2026

Search

Funds

October 9, 2026

FTSE 100

Funds